A study using real-world data found that patient reported outcome (PRO) monitoring among patients with lung cancer outside the setting of clinical trials was approximately 50%. These findings were published in JCO Oncology Practice.

Routine PRO monitoring is a critical component for improving symptomology and quality of life among patients with advanced solid malignancies. The objective of this study was to evaluate the real-world rate of PRO monitoring among patients with lung cancer. To that end, electronic medical records from the University of Pennsylvania and 2 affiliated community-based centers were retrospectively reviewed for PRO monitoring rates in 2019 in 1105 patients with lung cancer receiving cancer-directed systemic therapy.

The study population comprised 56.2% women, mean age 65.8±10.2 years, 19.6% Black or African American, 31.0% were receiving combination therapy, and 42.1% had stages IIIB-IV disease.


Continue Reading

Patients were cared for at the University center (site B; 73.2%) or 2 community-based centers: site A (8.9%) and site C (17.9%). The patient-level adherence to PRO monitoring was highest at site C (70.0%), followed by site B (47.1%) and site A (27.2%), or 49.4% overall. The encounter-level adherence to PRO monitoring was 55.4% overall and followed a similar pattern as the patient-level adherence rates.

At all sites, patients aged 65 years and older, Black race, or with unknown stage of disease were less likely than their counterparts to adhere to PRO monitoring (all P >.041). Compared with site A, patients visiting sites B or C (both P <.001) were more likely to undergo PRO evaluation.

The results of this study may be unique to the study sites and may not be generalizable.

These data indicated that real-world rates of PRO monitoring among patients with lung cancer was approximately 50% and depended on patient characteristics.

Disclosure: Some authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.

Reference

Takvorian SU, Anderson RT, Gabriel PE, et al. Real-world adherence to patient-reported outcome monitoring as a cancer care quality metric. JCO Oncol Pract. 2022;18(9):e1454-e1465. doi:10.1200/OP.21.00855